ML264 is primarily used in research settings as a potent and selective inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This enzyme plays a key role in regulating cortisol levels within tissues, particularly in the liver, adipose tissue, and brain. By inhibiting 11β-HSD1, ML264 helps reduce local cortisol production, which has implications for metabolic disorders such as type 2 diabetes, obesity, and metabolic syndrome. It is commonly applied in preclinical studies to investigate the effects of modulating glucocorticoid activity without systemic suppression of adrenal function. ML264 has shown promise in improving insulin sensitivity, reducing hepatic glucose output, and ameliorating dyslipidemia in animal models. Its selectivity makes it a valuable tool for studying tissue-specific glucocorticoid action and developing potential therapeutics targeting metabolic and cognitive diseases linked to cortisol dysregulation.